Slide 1: Preliminary Results for the year ended 31 December 2024
Transforming cancer care with the first FDA cleared medical device for the capture and harvest of circulating tumour cells Preliminary Results for the year ended 31 December 2024 Andrew Newland and Ian Griffiths 28 May 2025
Slide 2: Legal Disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal Disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be abound by the following conditions. The presentation slides which follow this notice and the oral presentation of wh
Slide 3: Large pharma strategy in place
Large pharma strategy in place • Next generation blockbuster drugs need companion diagnostics (new classes of drugs: ADCs, DDR inhibitors, immunotherapy combinations) • Clonal evolution of cancer critical to disease progression requires real-time non-invasive assessment (simple blood test) • Large p
Slide 4: 2024 Highlights
2024 Highlights Large Pharma DNA dual analysis • Four large pharma / biopharma contracts • Breakthrough DNA results demonstrating DNA – Eisai: HER2 breast cancer dual analysis of CTCs and ctDNA identifies key – AstraZeneca: DDR multiple cancers mutations not identified by ctDNA alone – AstraZeneca:
Slide 5: Financial Results for the year ended December 2024
Financial Results for the year ended 31 December 2024 Year ended Year ended 31 December 2024 31 December 2023 Key highlights: £'000 £'000 • 31% growth in revenues Statement of Comprehensive Income • FDA regulation over LDTs and grant funding environment constraining product sales, balanced by growth
Slide 6: Pharma services revenue build
Pharma services revenue build • Assay development (content) e.g. AstraZeneca AR assay for prostate cancer £600,000 • More than 2,000 cancer drugs in development1 with average cost per patient in Phase 2 cancer trials ~ US$180,000 • Clinical trial support at c. £3,000 per sample processed and gross m
Slide 7: Eisai: HER2-ADC in breast cancer
Eisai: HER2-ADC in breast cancer Global Japanese pharma company • Revenues >£3.7 billion3 >10,000 employees • >70 active oncology clinical trials >50,000 participants • ANGLE’s HER2 assay was used to detect and assess HER2 CTC status in a Phase 2 study of a HER2 antibody-drug conjugate (ADC) in an T
Slide 8: AstraZeneca: DDR multiple cancers
AstraZeneca: DDR multiple cancers Global pharma company with major oncology focus contributing to 39% of total product sales1 " It is through our science- • 459 active, interventional cancer clinical trials in 139,000 patients driven approach in targeting • Therapies targeting DNA Damage Response fo
Slide 9: AstraZeneca: AR prostate cancer
AstraZeneca: AR prostate cancer AR plays a pivotal role in Androgen Receptor (AR) detection assay for use in prostate cancer, especially castration-resistant prostate AstraZeneca’s prostate cancer studies cancer (CRPC). • Initial 12-month development phase worth £550,000, subsequently extended to £6
Slide 10: Recursion Pharmaceuticals
Recursion Pharmaceuticals • Clinical-stage biotechnology company leveraging technology, including machine learning and AI, to industrialise drug discovery • Five research programmes in clinical development, with a further two in preclinical development and 12 in early discovery • Agreement signed in
Slide 11: Other biopharma customers
Other biopharma customers © ANGLE plc 2025 11
Slide 12: DNA sequencing of CTCs (living) and ctDNA (dead)
DNA sequencing of CTCs (living) and ctDNA (dead) Hypothesis: Dual analysis provides critical information not otherwise available on cancer Retrospective Active cancer Prospective progression and for targeted treatment ctDNA ctDNA and CTC-DNA CTC-DNA selection Patient immune system Active disease bei
Slide 13: NuProbe: NGS pan-cancer gene panel
NuProbe: NGS pan-cancer gene panel “CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into • Cutting-edge genomics and molecular diagnostics company tangible improvements in patient care… • Option to exclusive gl
Slide 14: Growing body of third-party evidence
Growing body of third-party evidence Independent peer-reviewed publications at 31 December 2024 • FDA and EU clearance gives ANGLE first mover advantage in non-invasive repeat testing of intact cancer cells Clinically relevant biomarkers including: 88% published in • >270 Parsortix systems in use EG
Slide 15: Revenue build
Revenue build • ANGLE has both services and products businesses • The services business operates from ANGLE’s UK R&D and clinical laboratories – the R&D laboratory develops tests that can be run on CTCs for paying customers (known as assay development) – the clinical laboratory processes patient blo
Slide 16: Outlook
Outlook • Multiple large opportunities under discussion; binary in nature and timing uncertain • Modest growth in revenues is anticipated for the full year and dependent on the large opportunities, this may be exceeded • Following successful completion of large pharma contracts awaiting follow-up co
Slide 17: ANGLE plc contact details
ANGLE plc 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom angleplc.com © ANGLE plc 2025 17